{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:34:14Z","timestamp":1707525254417},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,18]]},"DOI":"10.7759\/cureus.43713","type":"journal-article","created":{"date-parts":[[2023,8,18]],"date-time":"2023-08-18T19:35:52Z","timestamp":1692387352000},"source":"Crossref","is-referenced-by-count":1,"title":["A Rare Case of Late-Onset Ertapenem-Induced Encephalopathy"],"prefix":"10.7759","author":[{"given":"Alexander J","family":"Teague","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sushan","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vishesh","family":"Paul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh203","article-title":"Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties","volume":"53","author":"Hammond ML","year":"2004","unstructured":"Hammond ML. Ertapenem: a group 1 carbapenem with distinct antibacterial and pharmacological properties. J Antimicrob Chemother. 2004, 53:27-9. 10.1093\/jac\/dkh203","journal-title":"J Antimicrob Chemother"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9812-x","article-title":"Delayed recovery from ertapenem induced encephalopathy: case-report and a possible mechanism","volume":"35","author":"Shea YF","year":"2013","unstructured":"Shea YF, Mok MY, Cheng KC, Hon FK, Chu LW. Delayed recovery from ertapenem induced encephalopathy: case-report and a possible mechanism. Int J Clin Pharm. 2013, 35:535-7. 10.1007\/s11096-013-9812-x","journal-title":"Int J Clin Pharm"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2019-231875","article-title":"Ertapenem-induced encephalopathy","volume":"13","author":"Adams R","year":"2020","unstructured":"Adams R, Chopra P, Miranda R, Calderon A. Ertapenem-induced encephalopathy. BMJ Case Rep. 2020, 13:e231875. 10.1136\/bcr-2019-231875","journal-title":"BMJ Case Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1007\/s40199-021-00425-5","article-title":"Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis","volume":"30","author":"Fern\u00e1ndez-Rubio B","year":"2022","unstructured":"Fern\u00e1ndez-Rubio B, Luque-M\u00e1rquez R, Gil-Navarro MV. Probable ertapenem-induced encephalopathy; case report and suggested alternatives for chronic prostatitis. DARU J Pharm Sci. 2022, 30:159-63. 10.1007\/s40199-021-00425-5","journal-title":"DARU J Pharm Sci"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P528","article-title":"Central nervous system toxicity associated with ertapenem use","volume":"45","author":"Duquaine S","year":"2011","unstructured":"Duquaine S, Kitchell E, Tate T, Tannen RC, Wickremasinghe IM. Central nervous system toxicity associated with ertapenem use. Ann Pharmacother. 2011, 45:127. 10.1345\/aph.1P528","journal-title":"Ann Pharmacother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0182046","article-title":"Risk factors associated with the development of seizures among adult patients treated with ertapenem: a matched case-control study","volume":"12","author":"Lee YC","year":"2017","unstructured":"Lee YC, Huang YJ, Hung MC, et al.. Risk factors associated with the development of seizures among adult patients treated with ertapenem: a matched case-control study. PLoS One. 2017, 12:e0182046. 10.1371\/journal.pone.0182046","journal-title":"PLoS One"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-017-0578-2","article-title":"Neurological adverse effects attributable to \u03b2-lactam antibiotics: a literature review","volume":"40","author":"Deshayes S","year":"2017","unstructured":"Deshayes S, Coquerel A, Verdon R. Neurological adverse effects attributable to \u03b2-lactam antibiotics: a literature review. Drug Saf. 2017, 40:1171-98. 10.1007\/s40264-017-0578-2","journal-title":"Drug Saf"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.2147\/IDR.S406852","article-title":"Ertapenem-induced neurotoxicity: a literature review of clinical characteristics and treatment outcomes","volume":"16","author":"Wang C","year":"2023","unstructured":"Wang C, Zhou Y, Zhou Y, Ye C. Ertapenem-induced neurotoxicity: a literature review of clinical characteristics and treatment outcomes. Infect Drug Resist. 2023, 16:3649-58. 10.2147\/IDR.S406852","journal-title":"Infect Drug Resist"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5414\/CN107247","article-title":"Acute prolonged neurotoxicity associated with recommended doses of ertapenem in 2 patients with advanced renal failure","volume":"80","author":"Wen MJ","year":"2013","unstructured":"Wen MJ, Sung CC, Chau T, Lin SH. Acute prolonged neurotoxicity associated with recommended doses of ertapenem in 2 patients with advanced renal failure. Clin Nephrol. 2013, 80:474-8. 10.5414\/CN107247","journal-title":"Clin Nephrol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1177\/2324709616689376","article-title":"Ertapenem-induced encephalopathy in a patient with normal renal function","volume":"5","author":"Sutton SS","year":"2017","unstructured":"Sutton SS, Jumper M, Cook S, Edun B, Wyatt MD. Ertapenem-induced encephalopathy in a patient with normal renal function. J Invest Med High Impact Case Rep. 2017, 5:2324709616689376. 10.1177\/2324709616689376","journal-title":"J Invest Med High Impact Case Rep"},{"key":"ref11","unstructured":"Invenz (ertapenem for injection) for intravenous or intramuscular use. (2012). Accessed. June 14, 2023: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021337s038lbl.pdf."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-018-0694-9","article-title":"Comparison of different methods for causality assessment of adverse drug reactions","volume":"40","author":"Behera SK","year":"2018","unstructured":"Behera SK, Das S, Xavier AS, Velupula S, Sandhiya S. Comparison of different methods for causality assessment of adverse drug reactions. Int J Clin Pharm. 2018, 40:903-10. 10.1007\/s11096-018-0694-9","journal-title":"Int J Clin Pharm"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/168976-a-rare-case-of-late-onset-ertapenem-induced-encephalopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T20:02:49Z","timestamp":1707508969000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/168976-a-rare-case-of-late-onset-ertapenem-induced-encephalopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,18]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.43713","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,18]]}}}